글로벌 세포 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

세포 치료 시장 분석

세포 치료 시장은 최근 몇 년 동안 재생 의학의 발전과 만성 질환의 유병률 증가에 힘입어 상당한 주목을 받고 있습니다. 세포 치료는 살아있는 세포를 투여하여 질병을 치료하거나 예방하는 것으로, 암, 당뇨병, 자가면역 질환과 같은 질환에 대한 혁신적인 솔루션을 제공합니다. 이 분야의 최근 발전에는 혈액 악성 종양에 대한 CAR-T 세포 치료의 획기적인 진전과 다양한 의료 응용 분야에 대한 줄기 세포 치료의 혁신이 포함됩니다. 이 시장은 점점 더 많은 임상 시험과 연구 개발에 대한 투자 증가, 특히 개인화된 의료 접근 방식이 특징입니다. 또한 규제 지원과 고급 치료 옵션에 대한 수요 증가가 시장 성장을 더욱 촉진하고 있습니다. 의료 시스템이 세포 치료 의 잠재력을 점점 더 인식함에 따라 시장은 지속적인 확장을 앞두고 있으며, 기존 회사와 바이오제약 분야의 신흥 기업 모두에게 기회를 제공합니다.

세포 치료 시장 규모

글로벌 세포 치료 시장 규모는 2023년에 177억 5천만 달러로 평가되었으며, 2031년까지 723억 5천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 19.20%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

세포 치료 시장 동향

“ 효과적인 치료법 개발”

세포 치료 시장은 혁신과 개인화된 의학에 대한 집중으로 인해 혁신적인 변화를 겪고 있습니다. 유전자 편집 및 세포 공학과 같은 기술의 최근 발전으로 인해 개별 환자의 요구에 맞는 보다 효과적인 치료법을 개발할 수 있게 되었습니다. 중요한 추세 중 하나는 특정 유형의 혈액 암 치료에 놀라운 성공을 보인 CAR-T 세포 치료법의 채택이 증가하고 있다는 것입니다. 이 추세는 부작용을 최소화하면서 치료 효능을 향상시키는 표적 치료법으로의 전환을 강조합니다. 전반적으로 세포 치료 시장은 빠르게 진화하고 있으며, 생물제약 회사와 학술 기관 간의 지속적인 연구와 협력으로 환자 치료에 혁명을 일으키고 건강 결과를 개선할 것을 약속하는 새로운 치료법의 길을 열었습니다.

보고서 범위 및 세포 치료 시장 세분화

Cell Therapy Market Definition

Cell therapy is a medical treatment that involves the administration of living cells to replace or repair damaged tissues and cells in the body. This innovative approach can utilize various types of cells, including stem cells, immune cells, and differentiated cells, to target specific diseases or conditions. Cell therapy aims to restore normal function by regenerating tissues, modulating immune responses, or directly killing cancer cells. It is a key component of regenerative medicine and has shown promise in treating a range of conditions, including cancers, genetic disorders, and degenerative diseases. Advances in cell therapy research and technology continue to enhance its effectiveness and applicability in clinical settings.

Cell Therapy Market Dynamics

Drivers

• Growing Incidence of Chronic Diseases

The growing incidence of chronic diseases, including cancer, diabetes, and neurodegenerative disorders, significantly fuels the demand for innovative therapeutic solutions such as cell therapy. As the global population ages and lifestyle-related health issues rise, the need for effective treatments has never been more critical. Cell therapies, which harness the body’s own cells or modified cells to combat disease, offer promising alternatives to traditional therapies. They aim to manage symptoms and address the root causes of diseases, particularly in conditions where conventional treatments may fall short. The advancements in cell processing and technology are further enhancing the efficacy and safety of these therapies, making them attractive options for patients and healthcare providers alike. Consequently, this increasing prevalence of chronic conditions is a significant market driver, prompting ongoing research, investment, and development in the cell therapy sector.

• Advancements in Research and Technology

 Continuous advancements in cell processing, engineering, and manufacturing techniques are significantly enhancing the effectiveness and safety of cell therapies, thereby attracting increased investments and interest in the field. Innovations in these areas enable researchers and developers to create more efficient methods for cell isolation, expansion, and modification, leading to higher-quality therapeutic products. Improved engineering techniques, such as gene editing and cell reprogramming, allow for the customization of therapies tailored to individual patient needs, further increasing their efficacy. In addition, enhanced manufacturing processes ensure consistency and scalability, which are crucial for meeting growing market demands. As a result, pharmaceutical companies and biotech firms are increasingly investing in research and development to explore new applications for cell therapies. This trend drives market growth positions cell therapy as a critical component in the evolving landscape of modern medicine, addressing various unmet medical needs.

Opportunities

• Expansion of Clinical Applications

The increasing acknowledgment of cell therapies for a diverse array of medical conditions is driving substantial growth in the market. Conditions such as cancers, autoimmune diseases, and degenerative disorders have traditionally posed significant treatment challenges. However, advancements in cell therapy techniques have shown promise in addressing these complex health issues, leading to improved patient outcomes. As more healthcare professionals and researchers recognize the potential of these therapies, there is an expanding focus on clinical trials and product development. This broadening scope enhances the therapeutic arsenal available to patients and opens significant opportunities for market expansion. Companies are investing in innovative research, positioning themselves to capitalize on this growing demand for effective cell-based treatments in various therapeutic areas.

• Advancements in Regenerative Medicine

The integration of cell therapy with regenerative medicine practices is revolutionizing treatment approaches for various medical conditions, presenting significant market opportunities. This synergy enables the development of innovative therapies aimed at restoring or replacing damaged tissues and organs, which is crucial for conditions such as heart disease, spinal cord injuries, and orthopedic disorders. By leveraging the unique properties of stem cells and other cell types, researchers can create targeted treatments that promote healing and enhance overall patient outcomes. Furthermore, as advancements in biomaterials and engineering techniques progress, the potential for creating functional tissue constructs increases. This convergence of cell therapy and regenerative medicine positions the market for substantial growth, as healthcare providers seek effective solutions that address the underlying causes of injuries and diseases, rather than just managing symptoms.

Restraints/Challenges

• High Manufacturing Costs

The production of cell therapies is characterized by complex and sophisticated processes that require advanced technology and specialized facilities. These intricacies often result in high manufacturing costs, which can create barriers to accessibility for healthcare providers and patients. The need for stringent quality control measures and compliance with regulatory standards further exacerbates these expenses. As a result, smaller companies may struggle to compete with larger firms that have more resources, limiting the overall scalability of cell therapies. This challenge restricts the availability of innovative treatments and raises concerns about equity in healthcare, as some patients may not have access to the latest therapies due to financial constraints.

•  Shortage of Skilled and Trained Professionals

The increasing demand for trained professionals in the field of cell therapy highlights a significant challenge: a shortage of skilled scientists and technicians. As the industry rapidly evolves and expands, the need for qualified personnel capable of developing, manufacturing, and administering cell therapies becomes more critical. This talent gap can hinder innovation and slow down progress in research and clinical applications. In addition, the lack of adequately trained individuals may lead to suboptimal implementation of new technologies and methodologies, potentially compromising the safety and efficacy of treatments. To fully realize the potential of cell therapy, it is essential to invest in education and training programs that cultivate a workforce equipped to meet the complexities of this advanced therapeutic area.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Cell Therapy Market Scope

The market is segmented on the basis of technology, type, cell type, cell source, application, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

Type

• Autologous
• Allogeneic

Cell Type

• Stem Cell
• Non-Stem Cell

Cell Source

• iPSCs
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cell

Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

End-User

• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

Cell Therapy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, technology, type, cell type, cell source, application, and end-users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global cell therapy market, thanks to its robust healthcare infrastructure and a high concentration of key industry players. The region's extensive network of healthcare facilities facilitates advanced treatment options and innovative research. In addition, a significant population grappling with chronic disorders further drives the demand for effective cell therapies, solidifying North America's position in this market.

Asia-Pacific region is poised for substantial growth in the global cell therapy market from 2024 to 2031. This expansion is fueled by increased government initiatives aimed at enhancing healthcare access and rising public awareness regarding health issues. Furthermore, the demand for advanced medical technologies to treat chronic conditions, combined with a large population and a growing emphasis on quality healthcare, positions the region as a key player in the cell therapy landscape.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Cell Therapy Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Cell Therapy Market Leaders Operating in the Market Are:

• Kolon TissueGene, Inc. (U.S.)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• MEDIPOST (South Korea)
• Stemedica Cell Technologies Inc. (U.S.)
• NuVasive Inc. (U.S.)
• Castle Creek Biosciences, Inc.  (U.S.)
• Cellectis (France)
• BioNTech IMFS (Germany)
• Pluri Biotech Ltd. (Israel)
• PRAXIS HEALTHCARE & PHARMACEUTICALS PVT. LTD. (U.S.)
• PHARMICELL Co. Ltd (South Korea)
• ANTEROGEN CO. LTD. (South Korea)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Celyad Oncology SA (Belgium)
• Regen BioPharma, Inc. (U.S.)
• Advancells (India)

Latest Developments in Cell Therapy Market

• In October 2023, Aurion Biotech initiated a phase 1/2 clinical trial in the United States to evaluate its cell therapy aimed at treating corneal edema. This study marks a significant advancement in exploring innovative treatment options for this eye condition. The trial's progression will be closely monitored as it seeks to demonstrate the therapy's safety and efficacy in patients
• 2023년 10월, Nkarta, Inc.는 CD19를 표적으로 하는 동종이식 CAR NK 세포 요법인 NKX019를 연구하기 위한 Investigational New Drug(IND) 신청에 대한 FDA 승인을 받았습니다. 이 요법은 까다로운 자가면역 질환인 루푸스 신염에 대한 새로운 치료 옵션을 제공하는 것을 목표로 합니다. 이 승인은 NKX019를 임상 시험으로 발전시키는 데 중요한 단계를 나타내며, 임상 시험에서 효과와 안전성이 평가됩니다.
• 2023년 6월, Vertex Pharmaceuticals Incorporated는 Lonza와 협력하여 Vertex의 연구용 줄기세포 치료제 생산을 강화하는 것을 목표로 합작 투자를 설립했습니다. 이 협력은 특히 1형 당뇨병(T1D) 치료제를 대상으로 하며, 임상 시험 프로그램인 VX-880과 VX-264에 집중합니다. 이 이니셔티브는 제조 공정을 간소화하고 이러한 유망한 치료제의 발전을 지원할 것으로 예상됩니다.
• 2023년 5월, 존슨앤존슨은 Cellular Biomedicine Group과 글로벌 협업 및 라이선스 계약을 체결하여 첨단 CAR-T 치료법을 공동 개발했습니다. 이 파트너십은 두 회사의 암 치료법 발전에 대한 의지를 반영하여 CAR-T 치료법의 효과를 혁신하고 향상시키는 것을 목표로 합니다. 이 협력은 종양학 분야에서 이러한 차세대 치료법의 개발을 가속화할 것으로 예상됩니다.
• 2023년 3월, Adaptimmune Therapeutics plc와 TCR2 Therapeutics는 고형 종양 치료에 초점을 맞춘 선도적인 세포 치료 기관을 설립하기 위한 전략적 파트너십을 발표했습니다. 이 제휴는 각 회사의 전문성과 리소스를 활용하여 이 어려운 종양학 분야에서 혁신적인 치료법을 발전시키도록 설계되었습니다. 이 협력은 고형 종양 암 환자의 치료 옵션과 결과를 개선하려는 공동의 의지를 반영합니다.        

SKU-28214